Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours are Epidermal Growth Factor Receptor 2 (HER-2) Amplified or Co-Expressing Epidermal Growth Factor Receptor 1 (HER-1) and HER 2

Trial Profile

Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours are Epidermal Growth Factor Receptor 2 (HER-2) Amplified or Co-Expressing Epidermal Growth Factor Receptor 1 (HER-1) and HER 2

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Varlitinib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals; PharmaNet Development Group
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Aug 2013 According to an Array BioPharma media release, positive results of this trial were reported in gastric cancer and a phase 2b study will be conducted.
    • 07 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01614522).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top